Anti-IL-27 Antibodies and Uses Thereof
AssigneeSurface Oncology, Inc.
InventorsJamie Strand, Jonathan Hill, Devan Moodley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
Claims33
1-80. (canceled)
A method for producing an antibody, or an antigen binding portion thereof, comprising culturing a cell to express the antibody or antigen binding portion thereof, wherein the antibody or antigen binding portion thereof comprises:
- (a) a heavy chain CDR1 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 9, 31, 53, 75, 97, or 119;
- (b) a heavy chain CDR2 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 10, 32, 54, 76, 98, or 120;
- (c) a heavy chain CDR3 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 11, 33, 55, 77, 99, or 121;
- (d) a light chain CDR1 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 17, 39, 61, 83, 105, or 127;
- (e) a light chain CDR2 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 18, 40, 62, 84, 106, or 128;
- and
- (f) a light chain CDR3 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs:
- 19, 41, 63, 85, 107, or 129.
A method for producing an antibody, or an antigen binding portion thereof, comprising culturing a cell to express the antibody or antigen binding portion thereof,
- wherein the antibody or antigen binding portion thereof comprises heavy and light chain CDRs, wherein:
- (a) the light chain CDR1 consists of N-XXXXXXLFSSNXKXYXX-C;
- (b) the light chain CDR2 consists of the sequence set forth in SEQ ID NO:
- 131;
- (c) the light chain CDR3 consists of N-XXXASAXXX-C;
- (d) the heavy chain CDR1 consists of the sequence set forth in SEQ ID NO:
- 122;
- (e) the heavy chain CDR2 consists of N-XXSSSXSYXYXXXXXXX-C;
- and
- (f) the heavy chain CDR3 consists of N-XXXXGRTSYTATXHNXXXX-C;
- wherein X is any amino acid.
Dependencies are inferred from the claim text.